孟鲁司特联合舒利迭治疗咳嗽变异性哮喘  

Effect of seretide plus montelukast on patients with cough variant asthma

作　　者：罗虹[1] 

机构地区：[1]四川省成都市四川省人民医院保健科,610072

出　　处：《临床肺科杂志》2008年第5期599-601,共3页Journal of Clinical Pulmonary Medicine

摘　　要：目的观察孟鲁司特与舒利迭联合治疗咳嗽变异性哮喘的效果。方法将100例咳嗽变异性哮喘门诊病例随机分成两组,分别使用舒利迭,孟鲁司特联合舒利迭各治疗12周,在治疗前后观察临床症状以及PEFR、FEV1的改变。结果两组治疗前后及治疗后第1秒用力呼气量(forced expiratory volume in 1 second,FEV1)和FEV1占预计值的百分数均有显著提高(P<0.05)。临床症状评分明显优于单用舒利迭(P<0.05)。结论应用舒利迭同孟鲁司特联合治疗咳嗽变异性哮喘能更迅速改善临床症状和肺功能,提示疗效相加作用。对单用舒利迭治疗仍不能有效控制咳嗽的患者可以考虑加用孟鲁司特。Objective To observe the clinical effect of seretide plus montdukast on patients with cough variant asthma. Methods One hundred patients with cough variant persistent asthma were randomly divided into two groups treated with seretide plus montelukast or seretide only for 12 weeks. The pulmonary function and clinical symptom before and after treatment were observed in the two groups. Results Both the forced expiratory volume in 1 second （ FEVl ） and the FEV1% after treatment improved significantly in the two groups （P 〈0. 05 ）. The FEVl and the FEV1% in the predicted value in the group plus montelukast were significantly higher than that in the group without montelukast at weekl2 after treatment （P 〈0. 05 ）. Conclusion The clinical improvement appears more rapidly in treatment by seretide plus montelukast than by seretide only.

关 键 词：孟鲁司特 舒利迭 咳嗽变异性哮喘 

分 类 号：R562.25[医药卫生—呼吸系统]